Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nuvectis Pharma (NVCT) EBITDA (2021 - 2026)

Nuvectis Pharma has reported EBITDA over the past 6 years, most recently at -$6.3 million for Q1 2026.

  • Quarterly results put EBITDA at -$6.3 million for Q1 2026, down 12.43% from a year ago — trailing twelve months through Mar 2026 was -$28.3 million (down 34.48% YoY), and the annual figure for FY2025 was -$27.6 million, down 38.93%.
  • EBITDA reached -$6.3 million in Q1 2026 per NVCT's latest filing, up from -$7.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.9 million in Q1 2022 and bottomed at -$7.8 million in Q3 2025.
  • Median EBITDA over the past 5 years was -$5.9 million (2022), compared with a mean of -$5.6 million.
  • Peak annual rise in EBITDA hit 39.83% in 2022, while the deepest fall reached 12704.35% in 2022.
  • Over 5 years, EBITDA stood at -$6.8 million in 2022, then dropped by 1.3% to -$6.9 million in 2023, then rose by 6.07% to -$6.4 million in 2024, then decreased by 18.11% to -$7.6 million in 2025, then grew by 17.82% to -$6.3 million in 2026.
  • Business Quant data shows EBITDA for NVCT at -$6.3 million in Q1 2026, -$7.6 million in Q4 2025, and -$7.8 million in Q3 2025.